Novartis AG (NVS)
NYSE: NVS · Real-Time Price · USD
122.44
-0.34 (-0.28%)
Sep 17, 2025, 4:00 PM EDT - Market closed
Novartis AG Revenue
Novartis AG had revenue of $14.84B in the quarter ending June 30, 2025, with 15.26% growth. This brings the company's revenue in the last twelve months to $55.19B, up 12.95% year-over-year. In the year 2024, Novartis AG had annual revenue of $51.72B with 10.85% growth.
Revenue (ttm)
$55.19B
Revenue Growth
+12.95%
P/S Ratio
4.31
Revenue / Employee
$727,251
Employees
75,883
Market Cap
237.64B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 51.72B | 5.06B | 10.85% |
| Dec 31, 2023 | 46.66B | 3.20B | 7.36% |
| Dec 31, 2022 | 43.46B | -513.00M | -1.17% |
| Dec 31, 2021 | 43.97B | -5.92B | -11.87% |
| Dec 31, 2020 | 49.90B | 1.22B | 2.51% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 422.82B |
| Johnson & Johnson | 90.63B |
| Merck & Co. | 63.62B |
| AbbVie | 58.33B |
| AstraZeneca | 56.50B |
| Eli Lilly and Company | 53.26B |
| Novo Nordisk | 49.11B |
| Thermo Fisher Scientific | 43.21B |
NVS News
- 2 days ago - Monte Rosa, Novartis Use AI-Powered Engine To Advance Immune Disease Treatments - Benzinga
- 2 days ago - Novartis, Monte Rosa strike $5.7 billion drug development deal - Reuters
- 5 days ago - Novartis Catches a ‘Sell.' Goldman Sachs Says the Stock Is Overvalued. - Barrons
- 7 days ago - US tariffs, pricing risks to be manageable for Big Pharma, Morningstar says - Reuters
- 8 days ago - Tourmaline Bio surges after Novartis $1.4 billion acquisition; analysts see strong fit - Invezz
- 8 days ago - This Biopharma Stock Is Soaring 58%. Novartis Is Acquiring It. - Barrons
- 8 days ago - Novartis to buy U.S. biotech in latest deal targeting firms in $1 billion to $3 billion range - Market Watch
- 8 days ago - Novartis Agrees to Buy Tourmaline Bio in $1.4 Billion-Dollar Deal - WSJ